Media thread, page-214

Orthocell (OCC, 40 cents)

Market capitalisation: $33 million

12-month total return: –17.5%

3-year total return: 0.9% a year

Estimated FY23 dividend yield: no dividend expected

Analysts’ consensus price target: n/a

Regenerative medicine company Orthocell (OCC) develops products for the repair of a variety of bone and soft tissue injuries, to regenerate mobility for patients. Orthocell’s platform technology has given rise to a portfolio of products that includes:

• CelGro, a collagen medical device that facilitates suture-less tissue repair and healing in a variety of dental and orthopaedic reconstructive applications;
• OrthoATI, the first injectable clinical-stage cellular therapy for the treatment of chronic tendon injuries, aimed at addressing a significant unmet clinical need for a safe, effective and non-surgical solution. The treatment is autologous, meaning uses each patient’s own tendon-derived cells to stimulate tendon regeneration and is delivered via a non-surgical ultrasound-guided injection. OrthoATI addresses a significant unmet clinical need in the healing of tendons that resist existing therapies. Orthocell is currently conducting two clinical trials with OrthoATI, the first is focused on the rotator cuff and the second on “tennis elbow” tendon defects.
• Striate, an application of CelGro approved for dental guided bone regeneration (GBR) applications, which is cleared for use in the US through the US Food & Drug Administration (FDA), 510(k) approval (for medical devices), Australia (Australian Register of Therapeutic Goods, ARTG) and Europe (CE Mark);
• Remplir, another application of CelGro, which is a collagen nerve wrap used in the repair of peripheral nerve injuries; it provides compression-free protection to the nerve, generating an ideal micro-environment to help nerve healing. Remplir helps in re-joining severed or severely damaged peripheral nerves, to restore function and sensation. Remplir recently received approval in Australia (ARTG) for surgical use.
• SmartGraft, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial.

The company’s other major products are autologous (using a patient’s own cells) cell therapies that aim to regenerate damaged tendons and cartilage tissue. Orthocell says its portfolio of musculoskeletal regenerative medicine applications has a total addressable annual market of US$17 billion, driven by the rising rate of musculoskeletal disorders and demand for efficient and cost-effective treatments.

In June, Orthocell signed a global exclusive licence and manufacturing agreement for Striate with BioHorizons Implant Systems, a part of the Nasdaq-listed Henry Schein, Inc., which has already seen OCC receive $21.5 million, net of fees. BioHorizons will exclusively market and distribute the Striate devices globally; Orthocell will manufacture them at its Perth facility, after increasing its capacity tenfold.

But the deal was transformative beyond the financial considerations, validating the company’s wider intellectual property suite of collagen-based regenerative devices. Orthocell says the BioHorizons deal proves the platform’s potential and positions the company to commercialise its Remplir nerve repair product in the US – the BioHorizons deal is restricted to the dental field only and does not prohibit a nerve or tendon deal.

OCC has a portfolio of world-leading regenerative medicine products. It’s early days for revenue, and the company makes a loss, but this is a story that many investors experienced in the long lead times of biotech like a lot.

Orthocell Limited (OCC)

Source: nabtrade

Some of the info here a bit dodgy.